WITHOUT PREJUDICE & SUBJECT TO CONTRACT UNTIL EXECUTED BY BOTH PARTIES DATED 16th OCTOBER 2009Compromise Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations
Dated February__23__,2009 SUPPLY AGREEMENT BETWEEN ANDSupply Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations
AMENDMENT AND WAIVER AGREEMENTAmendment and Waiver Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations
Certain portions of this Exhibit have been omitted pursuant to a request for “Confidential Treatment” under Rule 24b-2 of the Securities and Exchange Commission. Such portions have been redacted and bracketed in the request and appear as [*] in the text of this Exhibit. The omitted confidential information has been filed with the Securities and Exchange Commission.
ANDMaster Services Agreement for Non-Clinical Services • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations • England
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations • New York
consents, orders, registrations, qualifications or decrees the failure so to obtain would not, individually or in the aggregate, have a Material Adverse Effect and would not materially and adversely affect the consummation of the transactions contemplated by the Purchase Agreement;
Duly authorised for and on behalf ofTermination and Assignment Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations
Change Order for Additional Biostatistics & Medical Writing WorkChange Order for Additional Biostatistics & Medical Writing Work • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations
CONSULTANCY AGREEMENTConsultancy Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations
Catherine Soldano-Noble Executive Director, Marketing & Business Development Medpace, Inc. Cincinnati, OH 45212 Re: Amendment #2 to the Letter Agreement (“Amendment #2”) for certain initial services for the Amarin Trial A Study between Amarin Pharma...Amendment to the Letter Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations
The parties acknowledge that Medpace has already provided certain of the Initial Trial A Services, and the parties wish to amend Schedule A of the Initial Trial A Services Letter Agreement to include certain additional activities to be provided by Medpace prior to the parties entering into the MSA.
MASTER SERVICES AGREEMENT Between Medpace Inc. an Ohio Corporation Cincinnati, Ohio 45212 (“MEDPACE”) and Amarin Pharma Inc. a Delaware Company Mystic Packer Building, 12 Roosevelt Avenue Mystic, Connecticut, CT 06355 (“SPONSOR”) and Amarin...Master Services Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations • New York
This MASTER SERVICES AGREEMENT (the “Agreement”), dated as of the date of last signature hereof (the “Effective Date”), is between MEDPACE, SPONSOR and APIL. MEDPACE, SPONSOR and APIL are sometimes referred to herein individually as a “Party” and together as the “Parties”.
TERMINATION AND SEPARATION AGREEMENT AND RELEASETermination and Separation Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations • New York
This Termination and Separation Agreement and Release (“Agreement”) is entered into as of this ____ day of August, 2008 (the “Effective Date”), between Amarin Corporation plc (the “Company”) and Paul Duffy (the “Executive”).
BRIDGE LOAN AGREEMENTBridge Loan Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations • New York
which this Warrant is exercised. Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the certificates evidencing such Warrant Shares. If the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon such exercise, then the Company shall, not later than five Business Days thereafter and at its own expense, issue a new Warrant representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised. No fractional Ordinary Shares are to be issued upon the exercise of this Warrant and in lieu of any such fraction the Company shall pay the Holder an amount in cash equal
CONSULTANCY AGREEMENTConsultancy Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations • England
Catherine Soldano-Noble Executive Director, Marketing & Business Development Medpace, Inc. Cincinnati, OH 45212Amendment #5 to the Letter Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations
Re: Amendment #5 to the Letter Agreement (“Amendment #5”) for certain initial services for the Ethyl-EPA Hypertriglyceridemia Studies between Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, and Medpace, Inc. dated 1 December 2008, as amended on 19 January 2009 and as further amended on 30 January 2009, 5 May 2009 and 3 August 2009 (the “Initial Services Letter Agreement”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of October 12, 2009, is made by and among Amarin Corporation plc, a company incorporated under the laws of England and Wales (the “Company”), and the purchasers listed on Exhibit A hereto, together with their permitted transferees (each, a “Purchaser” and collectively, the “Purchasers”).
ContractLetter Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations • New York
AMENDMENTSecurities Purchase Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations • New York
This Amendment, dated as of October 12, 2009 (this “Amendment”), is made by and among Amarin Corporation plc, a company incorporated under the laws of England and Wales (the “Company”), and the other parties hereto (the “Investors”). Capitalized terms used herein without definition have the respective meanings set forth in the Securities Purchase Agreement dated May 13, 2008 (the “Agreement”).
